Stockhead’s Sarah Hughan sits down with Neurizon Therapeutics’ (ASX:NUZ) chair Sergio Duchini to get the short end of the long story on the company’s latest news.

The company has changed its name from PharmAust to reflect a promising new horizon for its neurodegenerative diseases treatments.

Amyotrophic Lateral Sclerosis is its main focus, the most common form of Motor Neurone Disease.

Tune in to hear Neurizon Therapeutics’ Sergio Duchini on the key aspects of the refresh, who its treatments could help, and more.

 

This video was developed in collaboration with Neurizon Therapeutics, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Read MoreHealth

Featured Companies

You might be interested in